Imagine writing a letter of life-and-death importance and trying to mail it only to discover that you have the wrong address, the wrong envelope and no way to buy a stamp. Robert Langer of the ...

The development of new medications brings numerous challenges. One key obstacle is that cells of the immune system will rapidly remove drugs and nanoparticles from circulation, resulting in less of ...

A human body producing its own medications on demand sounds like science fiction. Instead, researchers such as Northwestern Engineering’s Jonathan Rivnay are working today to make that technology a ...

Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer ...

(BOSTON) - A new strategy for engineering protein fusions -- to make specific cell-targeted drugs without side effects -- could enable a safer, more potent class of protein drugs. A team at the Wyss ...

SAN DIEGO--(BUSINESS WIRE)--Ablexis, LLC (“Ablexis”), a biopharmaceutical company focused on licensing its AlivaMab ® Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC ...

For decades, silicone has been used for short- and long-term implantable applications given its high level of biocompatibility. Today, a further characteristic—exceptional permeability—holds the key ...

Two Rutgers University engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of ...

This webinar series works with top educators, researchers (both academic and industrial), and government agencies in structural biology, medicinal chemistry, computational chemistry, and data science ...

Bone tissue engineering merges biomaterials science, cellular biology and biomechanics to regenerate or replace damaged bone. It involves designing scaffolds that mimic the extracellular matrix, ...

GT Biopharma Inc. GTBP on Monday said its recently implemented artificial intelligence-based technologies are improving drug discovery productivity and pipeline development efficiency, with the ...

Fail fast, fail cheap is a common clich in drug development. Studies project that anywhere from 4060% of potential drugs candidates fail in development due to absorption, distribution, metabolism, ...